These rates of CALR mutation seems to be diverse according to race and country; previously reported rates of CALR mutations for ET patients are 67.0% (considering ET patients without JAK2 or MPL mutation) in Austria [9], 15.5% (considering all ET patients) in Italy [19], 22.5% (considering all ET patients) in Taiwan [14], and 25.0% (considering all ET patients) in Han China [20]. Here, JAK2 is linked to essential thrombocythemia.